Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.

@article{Chendamarai2012RoleOM,
  title={Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.},
  author={E Chendamarai and Poonkuzhali Balasubramanian and Biju George and Auro Viswabandya and Aby Abraham and Rayaz Ahmed and Ansu Abu Alex and Saravanan Ganesan and Kavitha M. Lakshmi and Usha Sitaram and Sukesh Chandran Nair and Mammen Chandy and Nancy Beryl Janet and Vivi Miriam Srivastava and Alok Srivastava and Vikram Mathews},
  journal={Blood},
  year={2012},
  volume={119 15},
  pages={3413-9}
}
Data on minimal residual disease (MRD) monitoring in acute promyelocytic leukemia (APL) are available only in the context of conventional all-trans retinoic acid plus chemotherapy regimens. It is recognized that the kinetics of leukemia clearance is different with the use of arsenic trioxide (ATO) in the treatment of APL. We undertook a prospective peripheral blood RT-PCR-based MRD monitoring study on patients with APL treated with a single agent ATO regimen. A total of 151 patients were… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
15 Extracted Citations
25 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 15 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…